Fluoroquinolone antibiotics in infants and children

Infectious Disease Clinics of North America

Volumn 19, Issue 3, 2005, Pages 617-628

  Schaad, Urs B ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; BACTERIAL MENINGITIS; CARTILAGE; CHONDROPATHY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; EAR INFECTION; GASTROINTESTINAL INFECTION; HUMAN; LUNG DISEASE; MICROBIOLOGY; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; PEDIATRICS; POSTMARKETING SURVEILLANCE; REVIEW; RISK MANAGEMENT; STREPTOCOCCUS PNEUMONIAE; TENDINITIS; TENDON RUPTURE; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CARTILAGE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; INFANT;

EID: 23644450396     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2005.05.005     Document Type: Review

References (65)

1. R. Stahlmann Safety profile of the quinolones J Antimicrob Chemother 26 Suppl D 1990 31 44
2. R. Stahlmann, and H. Lode The quinolones - safety overview: toxicity, adverse events, and drug interactions V.T. Andriole The quinolones 1988 Academic Press London 201 203
3. A. Gough, N.J. Barsoum, L. Mitchell, E.J. McGuire, and F.A. de la Iglesia Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids Toxicol Appl Pharmacol 51 1979 177 187
4. W. Christ, T. Lehnert, and B. Ulbrich Specific toxicologic aspects of the quinolones Rev Infect Dis 10 Suppl 1 1988 141 146
5. G. Schluter Ciprofloxacin: toxicologic evaluation of additional safety data Am J Med 87 Suppl 5A 1989 37 39
6. U.B. Schaad, M.A. Salam, and Y. Aujard Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission Pediatr Infect Dis J 14 1995 1 9
7. D.F. McDonald, and H.B. Short Usefulness of nalidixic acid in treatment of urinary tract infections Antimicrob Agents Chemother 64 1964 628 631
8. R.R. Bailey, R. Natale, and A.L. Linton Nalidixic acid arthralgia Can Med Assoc J 107 1972 604 607
9. B. Ingham, D.W. Brentnall, E.A. Dale, and J.A. McFadzean Arthropathy induced by antibacterial fused n-alkyl-4-pyrodoine-3-carboxylic acids Toxicol Lett 1 1977 21 26
10. H. Tatsumi, H. Senda, S. Yatera, Y. Takemoto, M. Yamayoshi, and K. Onishi Toxicological studies on pipedimic acid: V. effect on diarthrodial joints of experimental animals J Toxicol Sci 3 1978 357 367
11. U.B. Schaad, and J. Wedgwood-Krucko Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity Infection 15 1987 165 168
12. Rumler W, von Rodhden L. Does nalidixic acid produce joint toxicity in childhood? In: Book of Abstracts of the 15th International Congress of Chemotherapy, Istanbul, Turkey; 1987. p. 1029-31.
13. D. Adam Use of quinolone in pediatric patients Rev Infect Dis 11 Suppl 5 1989 S1113 S1116
14. M. Nuutinen, J. Turtinen, and M. Uhari Growth and joint symptoms in children treated with nalidixic acid Pediatr Infect Dis J 13 1994 798 800
15. U.B. Schaad Use of the quinolones in pediatrics V.T. Andriole The Quinolones 3rd ed. 2000 Academic Press San Diego 455 475
16. R. Stahlmann, H.J. Merker, N. Hinz, I. Chahoud, J. Webb, and D. Neubert Ofloxacin in juvenile non-human primates and rats: arthropathia and drug plasma concentrations Arch Toxicol 64 1990 193 204
17. J.E. Burkhardt, M.A. Hill, and W.W. Carlton Morphologic and biochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin Toxicol Pathol 20 1992 246 252
18. M. Kato, S. Takada, S. Ogawara, and S. Takayama Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo Antimicrob Agents Chemother 39 1995 1979 1983
19. C. Forster, K. Kociok, and M. Shakibaei Integrins on joint cartilage chondrocytes and alterations by ofloxacin or magnesium deficiency in immature rats Arch Toxicol 70 1996 261 270
20. J. Vormann, C. Forster, and U. Zippel Effects of magnesium deficiency on magnesium calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity Calcif Tissue Int 61 1997 230 238
21. U.B. Schaad, E. Sander, J. Wedgwood, and T. Schaffner Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients Pediatr Infect Dis J 11 1992 1047 1049
22. U.B. Schaad, C. Stoupis, J. Wedgwood, H. Tschaeppeler, and P. Vock Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin Pediatr Infect Dis J 10 1991 723 729
23. D.A. Richard, S. Nousia-Arvanitakis, V. Sollich, B. Hampel, B. Sommerauer, U.B. Schaad, and the Cystic Fibrosis Study Group Oral ciprofloxacin versus intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety using ultrasonography and magnetic resonance imaging Pediatr Infect Dis J 16 1997 572 578
24. M. Arico, G. Bossi, and D. Caselli Long-term magnetic resonance survey of cartilage damage in leukemic children treated with fluoroquinolones Pediatr Infect Dis 14 1995 713 714
25. V.M. Gylys-Morin, P.C. Hajek, D.J. Sartoris, and D. Resnick Articular cartilage defects: detectability in cadaver knees with MR Am J Radiol 148 1987 1153 1157
26. D.A. Church, J.F. Kanga, and R.F. Kuhn Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations Pediatr Infect Dis J 16 1997 97 105
27. K.M. Pradhan, N.K. Arora, A. Jena, A.K. Susheela, and M.K. Bhan Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth Acta Paediatr 84 1995 555 560
28. D.B. Bethell, T.T. Hien, and L.T. Phi Effects on growth of single short courses of fluoroquinolones Arch Dis Child 74 1996 44 46
29. J.E. Burkhardt, J.N. Walterspiel, and U.B. Schaad Quinolone arthropathy in animals versus children Clin Infect Dis 25 1997 1196 1204
30. D. Gendrel, M. Chalumeau, F. Moulin, and J. Raymond Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet Infect Dis 3 2003 537 546
31. M. Chalumeau, S. Tonnelier, and P. d'Athis Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France Pediatrics 111 2003 e714 e719
32. V. Drosso-Agakidou, E. Roilides, and P. Papakyriakidou-Koliouska Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year Pediatr Infect Dis J 23 2004 346 349
33. B.B. Phillips, and T. David Pathogenesis and management of arthropathy in cystic fibrosis J R Soc Med 79 Suppl 12 1996 44 50
34. P.D. van der Linden, J. van de Lei, H.W. Nab, A. Knol, and B.H. Stricker Achilles tendinitis associated with fluoroquinolones Br J Clin Pharmacol 48 1999 433 437
35. P.D. van der Linden, M.C.J.M. Sturkenboom, R.M.C. Herings, H.G.M. Leufkens, and B.H. Stricker Fluoroquinolones and risk of Achilles tendon disorders: case-control study BMJ 324 2002 1306 1307
36. C.L. Yee, C. Duffy, P.G. Gerbino, S. Stryker, and G.J. Noel Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin Pediatr Infect Dis J 21 2002 525 529
37. Y. Khaliq, and G.G. Zhanel Fluoroquinolone-associated tendinopathy: a critical review of the literature Clin Infect Dis 36 2003 1404 1410
38. L.A. Mandell, L.R. Peterson, and R. Wise The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis 35 2002 721 727
39. D.C. Hooper New uses for new and old quinolones and the challenge of resistance Clin Infect Dis 30 2000 243 254
40. D.K. Chen, A. McGeer, J.C. De Azavedo, and D.E. Low Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada N Engl J Med 341 1999 233 239
41. P.L. Ho, R.W. Yung, and D.N. Tsang Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000 J Antimicrob Chemother 48 2001 659 665
42. P. Yagupsky, N. Porat, and D. Fraser Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel J Infect Dis 177 1998 1003 1012
43. S.B. Mannheimer, L.W. Riley, and R.B. Roberts Association of penicillin-resistant pneumococci with residence in a pediatric chronic care facility J Infect Dis 174 1996 513 519
44. C.B. Kronenberger, R.E. Hoffmann, D.C. Lezotte, and W.M. Marine Invasive penicillin-resistant pneumococcal infections: a prevalence and historical cohort study Emerg Infect Dis 2 1996 121 124
45. J. Gonzales, M. Georgiou, F. Alcaide, D. Balas, J. Linares, and A.G. de la Campa Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci Antimicrob Agents Chemother 42 1998 2792 2798
46. M.J. Ferrandiz, A. Fernoll, J. Linares, and A.G. de la Campa Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 44 2000 840 847
47. Blumer JL, Stern RC, Myers CM, et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis. Abstracts of 14th Internationl Congress on Chemotherapy, Kyoto, 1985.
48. H.R. Stutman, I. Shalit, M.I. Marks, R. Greenwood, S.A. Chartrand, and B.C. Hillman Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week-therapeutic trial in patients with cystic fibrosis Am J Med 82 Suppl 4A 1987 142 145
49. H. Peltola, M. Vaarala, O. Renkonen, and P.J. Neuvonen Pharmacokinetics of single dose of oral ciprofloxacin in infants and small children Antimicrob Agents Chemother 36 1992 1086 1090
50. H.G. Schaeffer, H. Strass, and J. Wedgwood Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients Antimicrob Agents Chemother 40 1996 29 34
51. T.T. Rubio, M.V. Miles, J.T. Lettiere, R.J. Kuhn, R.M. Echols, and D.A. Church Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation Pediatr Infect Dis J 16 1997 112 117
52. U.B. Schaad, J. Wedgwood, A. Ruedeberg, R. Kraemer, and B. Hampel Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis Pediatr Infect Dis J 16 1997 106 111
53. R. Fujii The use of norfloxacin in children in Japan Adv Antineopl Chemother 11 1992 219 232
54. M.A. Koyle, A. Barqawi, J. Wild, M. Passamaneck, and P.D. Furness Pediatric urinary tract infections: the role of fluoroquinolones Pediatr Infect Dis J 22 2003 1133 1137
55. S. Green, and G. Tillotson Use of ciprofloxacin in developing countries Pediatr Infect Dis J 16 1997 150 159
56. M.A. Salam, U. Dhar, W.A. Khan, and M.L. Bennish Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis Lancet 352 1998 522 527
57. R. Lang, S. Goshen, and A. Raas-Rothschild Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children Pediatr Infect Dis J 11 1992 925 929
58. A. Freifeld, and P. Pizzo Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients Pediatr Infect Dis J 16 1997 140 146
59. C.C. Patrick Use of fluoroquinolones as prophylaxis agents in patients with neutropenia Pediatr Infect Dis J 16 1997 135 139
60. L.E. Cuevas, P. Kazembe, G.K. Mughogho, G.S. Tilloston, and C.A. Hart Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adult in rural Africa: a comparision of ciprofloxacin and rifampicin J Infect Dis 171 1995 728 731
61. V. Krcmery, J. Filka, and J. Uher Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review Diag Microbiol Infect Dis 35 1999 75 80
62. X. Saez-Llorens, C. Mccoig, and J.M. Feris Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin Pediatr Infect Dis J 21 2002 14 22
63. R. Dagan, A. Arguedas, and U.B. Schaad Potential role of fluoroquinolone therapy in childhood otitis media Pediatr Infect Dis J 23 2004 390 398
64. E. Leibovitz, L. Piglansky, and S. Raiz Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tymopanocentesis study Pediatr Infect Dis J 22 2003 943 949
65. A. Arguedas, L. Sher, and E. Lopez Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure Pediatr Infect Dis J 22 2003 949 955